Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Rating of "Hold" from Analysts

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the stock, MarketBeat.com reports. Ten analysts have rated the stock with a hold recommendation. The average 12 month target price among brokerages that have covered the stock in the last year is $10.80.

VIGL has been the topic of several recent analyst reports. Guggenheim set a $8.00 target price on Vigil Neuroscience and gave the stock a "neutral" rating in a report on Thursday, May 22nd. Citigroup downgraded Vigil Neuroscience to a "market perform" rating in a research note on Thursday, May 22nd. HC Wainwright cut shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $14.00 to $8.00 in a research report on Tuesday, May 27th. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Finally, Wedbush cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and lowered their price objective for the stock from $13.00 to $8.00 in a research note on Thursday, May 22nd.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded down $0.01 on Tuesday, hitting $7.92. The company's stock had a trading volume of 419,588 shares, compared to its average volume of 1,203,455. Vigil Neuroscience has a 12 month low of $1.31 and a 12 month high of $7.95. The stock's 50-day moving average is $4.54 and its two-hundred day moving average is $2.94. The company has a market capitalization of $369.41 million, a price-to-earnings ratio of -3.86 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. Equities analysts expect that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

A number of large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC boosted its stake in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after purchasing an additional 8,358 shares during the period. Northern Trust Corp boosted its position in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after buying an additional 14,572 shares during the period. Barclays PLC boosted its position in shares of Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after buying an additional 19,436 shares during the period. Two Sigma Investments LP grew its holdings in shares of Vigil Neuroscience by 44.0% during the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock valued at $233,000 after buying an additional 41,836 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Vigil Neuroscience during the fourth quarter valued at $83,000. Institutional investors and hedge funds own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.